Tim Holt is a seasoned aesthetic medical device executive with 20+ years driving commercial launches and scaling breakthrough technologies like Fraxel, CoolSculpting and now Glacial® Rx. As President & CEO of R2 Technologies he blends product-first commercialization with clinical rigor to deliver cold-based, downtime-free treatments that prioritize safety, efficacy and patient experience across all skin types. Previously he helped steer ZELTIQ from early commercial hire to IPO and a $2.48B acquisition, and earlier played a pivotal role bringing Fraxel to market—demonstrating repeated success taking innovations from concept to industry-defining adoption. Tim pairs an operator’s focus on sales growth and loyalty programs with an intimate understanding of practitioner needs and clinical outcomes, rooted in an MBA and a BBA in Marketing. Not obvious from titles: he repeatedly collaborates with the same inventor teams across companies, showing rare long-term technical partnerships that accelerate product development and market trust. Based in Miami, he leads teams that aim not just to sell devices but to measurably improve patient lives through novel cryo-aesthetic science.
8 years of coding experience
5 years of employment as a software developer
MBA Management Lundy-Fetterman School of Business, MBA Management Lundy-Fetterman School of Business at Campbell University
Contributions:3 PRs, 27 pushes, 1 branch in 9 months
openapssettingopenapi3openapiswagger
Find and Hire Top DevelopersWe’ve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.
Request Free Trial
Tim Holt - President And CEO at R2 Technologies, Inc.